Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The generalisability of these reports is limited by their design and scale.

Who Took Part

The abstract describes 135 participants taking part.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

This was a randomised, double-blind, placebo-controlled study.

The primary outcome measure was change in IBS symptom severity; secondary outcomes included change in IBS-related quality of life.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Irritable Bowel Syndrome, Quality of Life, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords Symptom management.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 135 participants.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (European journal of nutrition), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.